Approval · Notice of Compliance 7610 · 2005
ENABLEX: Notice of Compliance 7610
Issued November 14, 2005
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 7610
- Date
- November 14, 2005
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
- Therapeutic class
- Muscarinic m3 selective receptor antagonist
Products in this notice
Medicinal ingredients
- DARIFENACIN HYDROBROMIDE 7.5 MG per TAB
- DARIFENACIN HYDROBROMIDE 15 MG per TAB